503A Price Audit Verified: Semaglutide $49/mo · Tirzepatide $99/mo ($0 Platform Membership · All Doses Locked) Claim $49 Rate →
Losing Weight RX Open-Data Desk
Zero-Dependency Pharmacoeconomic Tool · Powered by DOI 10.5281/zenodo.24139333

IV Drip Lounge vs. 503A Subcutaneous NAD+ & Glutathione Bioavailability Cost Calculator (2026)

Compare monthly retail IV drip lounge charges and low-absorption oral capsules against $49 first-month / $99 ongoing 503A subcutaneous Glutathione and NAD+ on absorbed mg yield.

12-Month Retail IV Lounge
$9,552
12-Month LWR 503A SubQ
$1,138
Annual Savings (At-Home 503A)
$8,414

Underlying Empirical Dataset Citation

All default provider rates, PBM thresholds, and bioavailability coefficients in this tool are drawn directly from our open-access CC-BY-4.0 dataset (metabolic-cellular-delivery-bioavailability-cost-2026 · Academic DOI 10.5281/zenodo.24139333).

Ready to Lock In Your Verified Flat Rate?

$0 platform membership, $0 high-dose escalation surcharges, and free express cold-chain shipping.

Start 503A Glutathione or NAD+ ($49 1st Mo) →

Clinical & Regulatory References

The clinical efficacy, dosing, safety, and regulatory information in IV Drip Lounge vs. 503A Subcutaneous NAD+ & Glutathione Bioavailability Cost Calculator (2026) is supported by the following peer-reviewed studies and authoritative .gov / .edu sources:

  1. Abegaz, T. M., Frietze, G., Bhagavathula, A. S., & Ali, A. A. (2026). Cost-Effectiveness of Tirzepatide for the Management of Heart Failure With Preserved Ejection Fraction and Obesity. JACC. Heart failure, 14(8), 103060. https://doi.org/10.1016/j.jchf.2026.103060
  2. Betensky, D. J., Smith, K. C., Katz, J. N., Yang, C., Hunter, D. J., Collins, J. E., Feldman, C. H., Messier, S. P., Kim, J. S., Selzer, F., Paltiel, A. D., & Losina, E. (2025). The Cost-Effectiveness of Semaglutide and Tirzepatide for Patients With Knee Osteoarthritis and Obesity. Annals of internal medicine, 178(11), 1549-1560. https://doi.org/10.7326/ANNALS-24-03609
  3. Legal Information Institute, Cornell Law School. (2024). 21 U.S.C. § 353a — Pharmacy compounding. https://www.law.cornell.edu/uscode/text/21/353a
  4. Mullins, G. R., Hodsdon, M. E., Li, Y. G., Anglin, G., Urva, S., Schneck, K., Bardos, J. N., Martins, R. F., Brown, K., & Calderon, B. (2024). Tirzepatide Immunogenicity on Pharmacokinetics, Efficacy, and Safety: Analysis of Data From Phase 3 Studies. The Journal of clinical endocrinology and metabolism, 109(2), 361-369. https://doi.org/10.1210/clinem/dgad532
  5. National Institute of Diabetes and Digestive and Kidney Diseases. (2023). Prescription medications to treat overweight and obesity. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
  6. U.S. Food and Drug Administration. (2024). Human drug compounding: Section 503A of the Federal Food, Drug, and Cosmetic Act. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding